Cantuzumab is a engineered antibody selectively targeting MUC1, a mucin frequently amplified in various malignancies , including lung adenocarcinoma . Its approach involves binding to MUC1, inducing an antibody-dependent cytotoxic response that leads to cancerous cell lysis . Clinical trials have investigated Cantuzumab's efficacy in treating th… Read More